DURHAM, N.C., SEPTEMBER 25, 2017 — Premier Research’s Chief Medical Officer will discuss development of immuno-oncology molecules at Outsourcing in Clinical Trials Southern California, September 27-28 in La Jolla.
Dr. Colin Hayward will address strategic and practical considerations for molecule development on the opening day of the annual gathering of pharma, biotech, and medical device leaders. Topics will include:
- Which indications to target.
- Combination strategies and other I/O development approaches you might consider.
- What’s involved in implementing a new I/O strategy for rare indications.
Premier Research’s oncology and rare disease experts understand the processes and strategies that work for each set of indications — and how to breach the divide when those approaches differ. With rare conditions accounting for more than one in five new cancer diagnoses, effectively joining these disciplines is more critical today than ever.
About Premier Research
Premier Research is a leading clinical development service provider that helps highly innovative biotech and specialty pharma companies transform breakthrough ideas into reality. The company has a wealth of experience in the execution of global, regional and local clinical development programs with a special focus on addressing unmet needs in areas such as analgesia, dermatology, medical device, neuroscience, oncology, pediatric, and rare disease. Premier Research operates in 84 countries and employs 1,100 professionals, including a strong international network of clinical monitors and project managers, regulatory, data management, statistical, scientific, and medical experts. They are focused on smart study design for advanced medicines that allow life-changing treatments.